696
Views
5
CrossRef citations to date
0
Altmetric
Clinical Studies

Expression of CD19+CD5+B Cells and IgA1-positive cells in Tonsillar Tissues of IgA Nephropathy Patients

, , , , , & show all
Pages 159-163 | Received 19 Sep 2010, Accepted 14 Dec 2010, Published online: 18 Feb 2011
 

Abstract

The hallmark of IgA nephropathy (IgAN) is the mesangial deposits of polymeric IgA. However, the source of IgA1 and the mechanism of deposition of IgA1 in the mesangium remain unknown. To better understand its pathogenesis, we investigated the expression of CD19+CD5+B cells and IgA1-positive cells in the tonsils of IgAN patients. Immunofluorescence was used to visualize the locations of CD19+CD5+B cells and IgA1-positive cells in the tonsils. In this study, it was demonstrated that CD19+CD5+B cells are usually found in germinal centers and in the capsule covering the upper parts of the nodules of lymphoid tissue (cap of the nodule). The expression of IgA1-positive cells in tonsil tissue can be seen in the cap of the nodule and subepithelial tissue. There is a significant relationship between IgA1 and CD19+CD5+B cells. The level of CD19+CD5+B cells is positively correlated to the severity of renal pathological changes. These findings suggest that CD19+CD5+B cells in the tonsils could have an impact on the pathogenesis of IgAN.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.